Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07DIX
|
||||
| Former ID |
DIB000025
|
||||
| Drug Name |
ALO-1567
|
||||
| Synonyms |
AL01567; 2-Fluorospiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Glaucoma [ICD9: 365; ICD10:H40-H42] | Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H9FN2O2
|
||||
| Canonical SMILES |
C1=CC=C2C(=C1)C3=C(C24C(=O)NC(=O)N4)C=C(C=C3)F
|
||||
| InChI |
1S/C15H9FN2O2/c16-8-5-6-10-9-3-1-2-4-11(9)15(12(10)7-8)13(19)17-14(20)18-15/h1-7H,(H2,17,18,19,20)
|
||||
| InChIKey |
JRGBXEJDIMXJAP-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 97677-19-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Aldose reductase | Target Info | Inhibitor | [1], [2] | |
| BioCyc Pathway | Methylglyoxal degradation III | ||||
| Acetone degradation I (to methylglyoxal) | |||||
| KEGG Pathway | Pentose and glucuronate interconversions | ||||
| Fructose and mannose metabolism | |||||
| Galactose metabolism | |||||
| Glycerolipid metabolism | |||||
| Metabolic pathways | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| PathWhiz Pathway | Fructose and Mannose Degradation | ||||
| Pyruvate Metabolism | |||||
| Pterine Biosynthesis | |||||
| Glycerolipid Metabolism | |||||
| Galactose Metabolism | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Polyol Pathway | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| References | |||||
| REF 1 | Metabolism of the aldose reductase inhibitor ALO1567 in man. Br J Clin Pharmacol. 1991 Aug;32(2):221-7. | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.